Multiple myeloma is deadly blood cancer which generally affects plasma cells found in bone marrow. The most commonly used first-line drug treatments for multiple myeloma include proteasome inhibitors, immunomodulatory drugs, and alkylating agents.
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion
- Market and Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 Drugs
- Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
Multiple myeloma is deadly blood cancer which generally affects plasma cells found in bone marrow. The most commonly used first-line drug treatments for multiple myeloma include proteasome inhibitors, immunomodulatory drugs, and alkylating agents. Although these have improved survival rates, but most patients generally enter the relapsed or refractory stage, thus possessing high medical needs for targeted therapies. In recent times, B cell maturation antigen (BCMA) has emerged out to be potential target for multiple myeloma owing to its high expression in malignant plasma cells. Several BCMA targeted therapies have entered the market which has demonstrated huge clinical success in multiple myeloma patients.
Carvykti developed by Johnson & Johnson is a BCMA-directed, genetically modified autologous T-cell immunotherapy, which involves reprogramming a patient’s own T-cells with a transgene encoding a chimeric antigen receptor (CAR) that identifies and eliminates cells that express the B-cell maturation antigen (BCMA). Recently in 2022, US FDA has granted approval to Carvykti ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The entrance of the drug in the market is expected to witness high growth rates owing to its enhanced efficacy over other approved BCMA targeted therapies.
Apart from this, two other BCMA targeted therapies have gained entry into the market. Blenrep is antibody drug conjugate which consists of anti-BCMA IgG1 monoclonal antibody conjugated to monomethyl auristatin F via non-cleavable linker. The drug was developed by GlaxoSmithkline and has entered the market in 2020. Later in 2021, Abecma developed by Bristol Meyer Squibb has entered the market. Abecma is second generation BCMA targeted CAR T-cell incorporating a single chain variable fragment, a 4-1BB co-stimulating domain and a CD3Zeta signaling domain, inducing cytotoxicity against MM cells independently of BCMA expression or soluble BCMA.
In addition to this, regulatory bodies in various regions are also providing various designations such as orphan, fast track, breakthrough to expedite the drug development and approval process. For instance in 2022, US FDA has granted orphan drug designation to IBI326, which is BCMA targeted CAR T cell therapy co-developed by Innovent and IASO Bio. In addition to this, FDA granted fast track designation to HPN217 for management of multiple myeloma. HPN217 is BCMA targeting tri-specific T-cell activating construct developed by Harpoon Therapeutics and is currently present in phase-I/II clinical trial. These rising initiatives by the government will have a positive impact on the global BCMA targeted therapy market during the forecast period.
The global BCMA targeted therapy market is highly competitive and consists of several players including Celegen Corporation, GlaxoSmithKline, Amgen, Gilead Science, Poseida Therapeutics, and others. Market players are actively investing in research and development of novel multiple myeloma therapies. These therapies include chimeric antigen receptor T cells, antibody-drug conjugate and Bi-specific antibodies. For instance, GlaxoSmithKline Plc. (GSK2857916) is developing the antibody drug conjugate drug for relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA. The robust pipeline of therapies for the treatment of multiple myeloma is expected to boost growth of the B-cell maturation Antigen (BCMA) targeted therapies market.
As per our report findings, the global BCMA targeted therapy market will surpass US$ 4 Billion by 2026. The market is driven by the shift in lifestyle of consumers, growing cases of multiple myeloma across the globe, and rising adoption of BCMA targeted therapies among patients. The development of new BCMA targeted drugs and investment in research and development projects by government and non-government organizations is further expected to boost the market growth during the forecast period.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366